Axis Direct's research report on Aurobindo Pharma
Aurobindohas launched (post approval)generic version of Renvela (Sevelamer Carbonate tablets – kidney ailment drug) in the US (market size of USD 1.9 bn as per IMS vs USD 745mn, in our view), following gRenvela OS^ (IMS market size of USD140mn) approval in Jun’17. Aurobindois the first and the only generic player to receive final approval for gRenvela (tablets + OS).
Outlook
we estimate the US market size of USD 745 mn for gRenvela tablets.We expect USD 116 mn in FY18 sales: USD 107mn from tablets and USD 9mn from OS. We expect additional generic competition in end FY18-19.
For all recommendations report, click here
Disclaimer: The views and investment tips expressed by investment experts/broking houses/rating agencies on moneycontrol.com are their own, and not that of the website or its management. Moneycontrol.com advises users to check with certified experts before taking any investment decisions.
Discover the latest Business News, Sensex, and Nifty updates. Obtain Personal Finance insights, tax queries, and expert opinions on Moneycontrol or download the Moneycontrol App to stay updated!
Find the best of Al News in one place, specially curated for you every weekend.
Stay on top of the latest tech trends and biggest startup news.
Read More
